Disease & disorder
B-cell non-Hodgkin lymphoma
MONDO:0015759
The most common type of non-Hodgkin lymphoma. It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma. -- 2003
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
Loading mapped interventions…
MONDO disease family
Loading verified ontology relationships…
Recruiting studies by city
Loading research-site locations…
Trial status
Loading…
Trial phase
Loading…
Study start year
Loading…
Investigated drug interventions
Loading…
Background context
B-cell non-Hodgkin lymphoma
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
11 shownT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)NCT06343311 · 2024-06-01
RECRUITINGPredictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer PatientsNCT03787056 · 2018-12-04
RECRUITINGLong-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsNCT07474051 · 2026-01-29
ENROLLING_BY_INVITATIONStudy of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or LymphomasNCT05415098 · 2022-09-30
UNKNOWNObservational Study of People Living With HIV Treated With CD19-directed CAR T CellNCT05784415 · 2021-05-22
COMPLETEDClinical and Immunological Evolution of Covid-19 Occurring in a Context of Non-Hodgkin LymphomaNCT04641806 · 2020-11-01
WITHDRAWNStudy to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)NCT03598608 · 2018-10-17
TERMINATEDHORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday LifeNCT03000192 · 2016-08-01
UNKNOWNSafety Study of SEA-CD40 in Cancer PatientsNCT02376699 · 2015-02-28
TERMINATEDMulti-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating FactorNCT01459653 · 2010-03-01
COMPLETEDA Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaNCT00457782 · 2007-04-01
COMPLETEDDrugs being studied
Research locations
BerlinGermany2ClevelandOhio, United States2LondonUnited Kingdom2Los AngelesCalifornia, United States2LyonFrance2ManchesterUnited Kingdom2NottinghamUnited Kingdom2PhiladelphiaPennsylvania, United States2Pierre-BéniteFrance2PortlandOregon, United States2Salt Lake CityUtah, United States2AlbuquerqueNew Mexico, United States1
Leading sponsors
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.